Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury
Status:
Completed
Trial end date:
2021-01-19
Target enrollment:
Participant gender:
Summary
The study is a prospective, randomized, placebo-controlled, single-blind phase 2 clinical
study of the efficacy and safety of CERC-002, a potent inhibitor of LIGHT, for the treatment
of patients with COVID-19 pneumonia who have mild to moderate ARDS.
LIGHT is a cytokine in the TNF super family (TNFSF14) which drives inflammation and induces
many other cytokines including IL-1, IL-6 and GM-CSF. LIGHT levels have been shown to be
elevated in COVID-19 infected patients and inhibiting LIGHT is hypothesized to ameliorate the
cytokine storm which has shown to be a major factor in progression of ARDS.
The study will assess the efficacy and safety of CERC-002 in patients with severe COVID-19
over a 28 day period as single dose on top of standard of care.